Oryzon acaba de cerrar varios préstamos a largo plazo con distintas entidades bancarias por un importe total de 10,5 millones de euros. Con la suscripción de dichos préstamos se da por finalizada l...
Read moreEpigenetic approaches to modify the progression of various neurodegenerative diseases focus on producing changes in patterns of gene expression in neurons and also in glia cells and are of interest fo...
Read moreOryzon Genomics, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in oncology and neurodegenerative diseases, announced that the company was granted two unsecured...
Read moreCarlos Buesa, Oryzon’s Co-Founder, President and Chief Executive Officer commented, " The success of this capital raise is affirmation that investors , some of them specialized in the epigenetics fi...
Read moreThe agreement between Oryzon Genomics and Roche, a company specializing in developing oncology drugs, encompasses researching, developing and marketing inhibitors of LSD1 for oncology, hematology and ...
Read moreRoche (SIX: RO, ROG; OTCQX: RHHBY) and Oryzon Genomics SA today announced they have entered into a worldwide collaboration to research, develop and commercialize inhibitors of Lysine Specific Demethyl...
Read morehe First Specific LSD1 Inhibitor to Enter the Clinic. Barcelona, Spain. January 16th, 2014. ORYZON, a biopharmaceutical company with a strong focus on epigenetics, hasannounced that has receiv...
Read more